• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Alzheimer's Disease 
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for Alzheimer's Disease trials

DOWNLOAD BROCHURE GET IN TOUCH

Effective solutions for advancing Alzheimer's Disease research

Alzheimer’s Disease (AD) severely impacts daily life for people living with this form of dementia, but clinical trials investigating disease-modifying treatments unfortunately suffer high failure rates. That's where Signant's unrivaled solutions and expertise can help.

Navigate Alzheimer's Trial Challenges & Meet Your Goals

  • Optimize ClinRO & Endpoint Data
  • Eliminate Rater Error & Variability
  • Safeguard Data Quality Throughout a Program
  • Increase Participant Retention in Long-Term Follow up Periods
  • Increase Signal Detection Opportunities
  • Optimize ClinRO & Endpoint Data

    Optimize ClinRO & Endpoint Data

    As the first eClinical company to develop electronic assessments for dementia trials, our mature eCOA platform provides validated electronic versions of common AD study scales such as ADAS-Cog and MMSE. Advanced features such as preset workflows, edit checks, and audio/video recording capabilities ensure scoring accuracy and consistency. When applied in conjunction with our Blinded Data Analytics, published data show a significant reduction in errors as well as increased ClinRO and endpoint data reliability.

  • Eliminate Rater Error & Variability

    Eliminate Rater Error & Variability

    Our team of Alzheimer’s clinical experts qualify, train, and certify raters to ensure accurate COA scoring and administration. We perform independent reviews of audio, video and data, and recalibrate raters throughout the study as needed to maintain standards, and our technology allows for gatekeeping by qualification status to further safeguard your study data and prepare for regulatory reviews.

  • Safeguard Data Quality Throughout a Program

    Safeguard Data Quality Throughout a Program

    Reliable and accurate data is the cornerstone to any successful clinical trial but especially vital in Alzheimer’s studies which suffer extremely high failure rates. Signant’s in-study data quality monitoring and analytics solutions can identify, correct, and prevent common issues such as errors, bias, or fraud.

  • Increase Participant Retention in Long-Term Follow up Periods

    Increase Participant Retention in Long-Term Follow up Periods

    Participating in clinical trials is difficult for people living with Alzheimer’s. Signant SmartSignals solutions simplify participation for patients and caregivers – from eConsent to Patient Concierge and Telemedicine, leverage our solutions to reduce the burden on patients and caregivers during long-term follow up studies, improving retention in these critical phases.

  • Increase Signal Detection Opportunities

    Increase Signal Detection Opportunities

    Study teams require sensitive and accurate measures to detect signal in AD studies. Our clinical experts ensure cognitive and functional assessments are done to the highest standard. In addition, Signant’s proprietary computerized Cognitive Assessments help researchers precisely detect subtle changes in over time to understand a drug’s effect on cognitive function.

Comprehensive Alzheimer's Disease Experience: Phases I-IV

0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore our Alzheimer's Disease trial resources
SOLUTION BROCHURE

Alzheimer's Disease Trial Solutions Overview




GET INSIGHTS
VIDEO

Alzheimer's Disease Trial Solutions




WATCH [2 MIN]
WHITE PAPER

Order Amid the Chaos:
Maximize the Quantity and
Quality of Data in Remote
Alzheimer’s Disease Scale
Administrations

 
READ WHITEPAPER

Solutions Tailored for Alzheimer's Trials

Ready to learn more?

Discover how Signant can support your current or upcoming Alzheimer's trials. 

DOWNLOAD BROCHURE GET STARTED